# Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors

> **NCT01202032** · PHASE1 · COMPLETED · sponsor: **Centre Leon Berard** · enrollment: 36 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed

## Interventions

- **DRUG:** Association of Bevacizumab (BVC)+ Pazopanib (PZP)

## Key facts

- **NCT ID:** NCT01202032
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-03
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2016-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202032, "Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01202032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*